Axatilimab plus CAR-T cells for aggressive lymphoma

This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.

This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.

This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.

This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.

This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.

This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.